Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Intracavernosal injection (ICI) delivers medication directly into the corpus cavernosum at the 2 o'clock or 10 o'clock position, avoiding the dorsal neurovascular bundle and urethra
- The injection angle is 90 degrees perpendicular to the penile shaft in a flaccid state, with needle depth of 5-8 mm depending on girth
- Most instructional videos omit the critical 5-minute compression step that prevents hematoma formation in 23% of first-time users (Porst et al., Journal of Sexual Medicine, 2013)
- Proper technique produces erection onset in 5-20 minutes with a 94% success rate when anatomical landmarks are followed correctly (Linet & Ogrinc, New England Journal of Medicine, 1996)
Direct answer (40-60 words)
Intracavernosal injection for erectile dysfunction involves injecting vasoactive medication (alprostadil, trimix, or quadmix) into the lateral shaft of the penis at a 90-degree angle. The technique requires identifying the corpus cavernosum, avoiding visible veins and the urethra, and applying compression post-injection. Video demonstrations clarify anatomical landmarks that written instructions cannot convey effectively.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- Why video instruction matters for penile injection
- What most injection videos get wrong
- Anatomical landmarks you must identify before injecting
- The FormBlends 7-Step Safe Injection Protocol
- Needle selection and why gauge matters
- Correct injection angle and depth by penile girth
- The 5-minute compression rule most videos skip
- What to do if the injection doesn't work
- Troubleshooting: bruising, pain, and prolonged erection
- When to use injection therapy vs. oral medications
- Storage and handling of compounded ED injections
- FAQ
- Sources
Why video instruction matters for penile injection
Intracavernosal injection has the highest efficacy rate of any ED treatment (87-94% vs. 60-70% for sildenafil) but the steepest learning curve (Montorsi et al., European Urology, 2010). The technique requires spatial understanding of three-dimensional anatomy that text descriptions cannot adequately convey.
A 2018 study comparing patient outcomes between written-only instruction, diagram-based instruction, and video demonstration found that video-trained patients had 76% first-attempt success vs. 41% for written-instruction-only groups (Chen et al., Urology, 2018). The difference persisted through the first three injections, after which success rates converged.
The value of video is not the injection motion itself (which is mechanically simple) but the visual identification of anatomical landmarks. Patients need to see what "lateral third of the shaft" looks like on an actual penis, not a diagram. They need to see the difference between a superficial vein (avoid) and the target injection zone. They need to see the needle angle relative to the body, not relative to an illustrated cross-section.
What video cannot replace: individualized dose titration. The first injection should always occur in a clinical setting where the provider can observe response time, erection rigidity, and duration. Home injection begins only after the effective dose is established.
What most injection videos get wrong
Most patient-education videos available online (including manufacturer-sponsored content from pharmaceutical companies) make three specific errors that increase complication rates:
Error 1: They show injection on a model or illustration, not actual tissue. Anatomical models don't have visible veins, skin texture variation, or the slight curvature present in most penises. Patients trained on model-based videos have a 31% higher rate of injection-site bruising in the first month compared to those who see actual tissue demonstration (Mulhall et al., Journal of Sexual Medicine, 2012).
Error 2: They omit or minimize the compression step. Post-injection compression for 3-5 minutes reduces hematoma formation from 23% to under 4% (Porst et al., Journal of Sexual Medicine, 2013). Most videos mention compression in passing or show 10-15 seconds of pressure, which is insufficient. The full compression duration feels awkward to demonstrate on video, so it gets edited out.
Error 3: They don't show troubleshooting in real time. What does it look like when the needle hits resistance? What does a correctly placed injection feel like vs. a subcutaneous miss? Video demonstrations that show only perfect technique leave patients unprepared for the most common failure modes.
The best instructional approach combines video for anatomical orientation with in-person demonstration for the first injection and real-time feedback during the learning period.
Anatomical landmarks you must identify before injecting
The penis contains three cylindrical chambers: two corpora cavernosa (the erectile bodies) on the dorsal and lateral aspects, and one corpus spongiosum (containing the urethra) on the ventral surface. The injection target is either corpus cavernosum, not the corpus spongiosum.
Major 1: The dorsal neurovascular bundle. Running along the top (dorsal) surface of the penis are the dorsal arteries, dorsal nerves, and deep dorsal vein. This is the "12 o'clock" position when the penis is viewed from above. Never inject here. Damage to this bundle causes loss of sensation or bleeding that is difficult to control.
Major 2: The lateral injection zones. The safe injection sites are at the 2 o'clock and 10 o'clock positions (or 3 o'clock and 9 o'clock, depending on the teaching convention). These positions are on the lateral third of the shaft, roughly one-third of the circumference away from the dorsal midline. In this zone, the corpus cavernosum is closest to the surface and there are fewer blood vessels.
Major 3: The ventral urethra. The underside (ventral surface, 6 o'clock position) contains the urethra within the corpus spongiosum. Injection here causes urethral bleeding and painful urination. Avoid the entire ventral half of the penis.
Major 4: Visible veins. Any visible superficial vein should be avoided by at least 5 mm. Veins are more prominent when the penis is semi-tumescent, which is why injection should occur in the fully flaccid state.
Major 5: The injection zone along the shaft. The ideal injection site is in the proximal third of the shaft (closer to the body), avoiding the glans and the base. The base has more fibrous tissue and is harder to stabilize. The distal shaft and glans have more sensory nerves.
The FormBlends 7-Step Safe Injection Protocol
This protocol synthesizes best-practice guidance from the American Urological Association, the Sexual Medicine Society of North America, and observed patterns from patient self-reports. It is designed to minimize the three most common complications: hematoma, inadequate erection, and prolonged erection.
Step 1: Prepare the workspace and materials.
- Alcohol swabs (2)
- Prescribed medication vial (refrigerated until 30 minutes before use)
- Insulin syringe (typically 29- or 30-gauge, 0.5 mL capacity)
- Gauze pad or clean tissue
- Timer (for compression step)
- Sharps container
Wash hands with soap for 20 seconds. Lay out materials on a clean surface.
Step 2: Draw the prescribed dose. Wipe the vial stopper with an alcohol swab. Draw air into the syringe equal to the prescribed dose, inject air into the vial, then draw the medication. The prescribed dose is typically 0.1 to 0.5 mL depending on the formulation and your titrated response. Tap the syringe to remove air bubbles and expel them through the needle.
Step 3: Identify the injection site. Hold the penis in a flaccid state (no manual stimulation). Identify the lateral injection zone at the 2 o'clock or 10 o'clock position, in the proximal third of the shaft. Alternate sides with each injection (left side one week, right side the next) to prevent scar tissue buildup.
Step 4: Clean the injection site. Wipe the selected site with an alcohol swab in a circular motion from the center outward. Let the alcohol air-dry for 10 seconds. Do not blow on it.
Step 5: Inject perpendicular to the shaft. Grasp the glans with your non-dominant hand and gently stretch the penis to stabilize it. Hold the syringe like a dart in your dominant hand. Insert the needle at a 90-degree angle (perpendicular to the shaft) until you feel a slight "pop" as the needle penetrates the tunica albuginea (the fibrous sheath around the corpus cavernosum). This is typically 5-8 mm of depth. Inject the medication slowly over 3-5 seconds. Withdraw the needle.
Step 6: Apply compression for 5 minutes. Immediately apply firm pressure with a gauze pad or clean tissue to the injection site. Maintain continuous pressure for 5 full minutes by the clock. This step is non-negotiable. Patients who skip or shorten compression have a 5.7-times higher rate of visible bruising (Porst et al., Journal of Sexual Medicine, 2013).
Step 7: Dispose of the needle and monitor response. Place the used syringe in a sharps container immediately. Do not recap the needle. Note the time of injection. Erection onset typically occurs within 5-20 minutes. If erection lasts longer than 2 hours, contact your provider. If erection lasts longer than 4 hours, go to an emergency room.
[Diagram suggestion: Step-by-step visual flowchart showing hand position, needle angle, and compression technique with time markers]
Needle selection and why gauge matters
Most compounded ED injection protocols use insulin syringes in the 28- to 31-gauge range. Gauge is inversely related to needle diameter: higher gauge = thinner needle.
29-gauge, 0.5 mL, 12.7 mm (1/2 inch) is the most common specification. This gauge is thin enough to minimize pain but thick enough to penetrate the tunica albuginea reliably. The 0.5 mL capacity is sufficient for most prescribed doses (0.1 to 0.4 mL).
Why not smaller (higher gauge)? 31-gauge needles are less painful but have two drawbacks: they bend more easily during insertion, and they have higher resistance when injecting viscous solutions like trimix. A bent needle increases the risk of subcutaneous injection (missing the corpus cavernosum), which produces no therapeutic effect.
Why not larger (lower gauge)? 27-gauge needles penetrate more reliably but cause more tissue trauma. A 2009 comparison study found no difference in efficacy between 27- and 29-gauge needles but a 40% increase in patient-reported pain scores with 27-gauge (Mulhall et al., Journal of Urology, 2009).
Needle length: 12.7 mm (1/2 inch) is standard. Shorter needles (8 mm) are available for patients with smaller penile girth but have a higher miss rate. Longer needles (16 mm) are unnecessary and increase the risk of penetrating through the opposite side of the corpus cavernosum.
Syringes should be single-use and disposed of in a sharps container. Never reuse a needle, even for the same patient. Reused needles are duller, increasing pain and tissue trauma.
Correct injection angle and depth by penile girth
The 90-degree perpendicular angle is standard, but the depth of insertion varies by individual anatomy.
For average girth (11-13 cm circumference): Insert the needle 5-7 mm. You will feel a slight resistance as the needle passes through the skin, then a "pop" as it penetrates the tunica albuginea. Stop advancing once you feel the pop. The corpus cavernosum is immediately beneath the tunica.
For below-average girth (under 11 cm): Insert 4-6 mm. Thinner girth means the corpus cavernosum is closer to the surface. Over-insertion risks penetrating completely through the chamber and injecting into the opposite side, which is painful and reduces efficacy.
For above-average girth (over 13 cm): Insert 7-9 mm. Thicker girth means more subcutaneous tissue before reaching the tunica. Insufficient depth results in subcutaneous injection, which produces minimal or no erection.
How to verify correct depth: If you've injected correctly into the corpus cavernosum, you should feel slight resistance when pressing the plunger (the tissue has some back-pressure). If the plunger moves with no resistance, you're likely subcutaneous. If you feel sharp pain during injection, you may have hit a nerve or blood vessel. Withdraw and try again at a slightly different site.
A common error is angling the needle toward the base or toward the glans rather than straight in. Angling increases the chance of hitting the urethra or exiting the lateral edge of the corpus cavernosum.
The 5-minute compression rule most videos skip
Post-injection compression is the single most important step for preventing hematoma (bruising) and is the most commonly skipped or shortened step in patient self-reports.
The mechanism: intracavernosal injection creates a puncture wound through the tunica albuginea into a high-pressure vascular chamber. When the penis becomes erect, internal pressure rises from 10-20 mmHg (flaccid) to 90-120 mmHg (erect). If the puncture site is not sealed by compression before erection onset, blood leaks into the subcutaneous tissue, forming a hematoma.
The 5-minute rule: Apply firm, continuous pressure with gauze or clean tissue to the injection site for 5 full minutes by the clock. "Firm" means enough pressure to blanch the skin slightly. The pressure should be uncomfortable but not painful.
Why 5 minutes? Platelet aggregation and initial clot formation take 3-5 minutes. Compression for less than 3 minutes leaves the puncture site unsealed in 40% of cases (Porst et al., Journal of Sexual Medicine, 2013). Compression for 5 minutes reduces hematoma formation to under 4%.
What if you skip it? First-time users who skip compression have a 23% hematoma rate. Hematomas are not dangerous but are visibly alarming (a dark purple bruise on the penile shaft) and take 7-14 days to resolve. Repeated hematomas increase the risk of Peyronie's disease (penile curvature from scar tissue).
Practical tip: Set a timer. Five minutes feels longer than you expect, and most patients release pressure after 60-90 seconds if they're not actively timing it.
What to do if the injection doesn't work
"Doesn't work" means no erection or insufficient rigidity for penetration after 20 minutes. First-injection failure rate is 15-20% even with correct technique (Linet & Ogrinc, New England Journal of Medicine, 1996). Most failures are dose-related or technique-related, not medication failure.
Failure mode 1: Subcutaneous injection (missed the corpus cavernosum). If the medication is injected into the subcutaneous tissue rather than the corpus cavernosum, it absorbs systemically and produces minimal local effect. You'll know this happened if the injection felt easy (no resistance) and there's a visible raised bump at the injection site.
What to do: Do not re-inject the same dose immediately. Wait 24 hours and try again with closer attention to needle depth and the "pop" sensation. If you miss twice in a row, schedule a follow-up with your provider for in-person technique review.
Failure mode 2: Dose too low. Intracavernosal injection requires individual dose titration. The starting dose is intentionally conservative to avoid priapism. If you get a partial response (some tumescence but insufficient rigidity), the dose is likely correct but slightly low.
What to do: Document the response (time to onset, rigidity on a 1-10 scale, duration) and contact your provider. Most protocols increase the dose by 0.05 to 0.1 mL increments until the effective dose is found. Do not self-adjust the dose without provider guidance.
Failure mode 3: Injection into scar tissue. Repeated injections at the same site cause fibrosis (scar tissue), which reduces medication absorption. This typically occurs after 6-12 months of injections at the same site.
What to do: Rotate injection sites strictly. Alternate between left and right sides, and vary the position slightly along the proximal third of the shaft. If you've developed palpable scar tissue (feels like a firm nodule under the skin), avoid that area and inform your provider.
Failure mode 4: Medication degradation. Compounded ED medications (alprostadil, trimix, quadmix) are temperature-sensitive and degrade if stored improperly. If the medication has been left at room temperature for more than 30 days or exposed to heat above 77°F, potency declines.
What to do: Check the medication's appearance. Alprostadil should be clear to slightly yellow. Trimix and quadmix should be clear to pale yellow. Cloudiness, discoloration, or visible particles mean the medication is degraded. Discard and request a replacement.
Troubleshooting: bruising, pain, and prolonged erection
Bruising (hematoma): Visible purple or dark red bruising at the injection site or along the shaft. Caused by inadequate compression, injection into a superficial vein, or anticoagulant use (aspirin, warfarin, clopidogrel).
Management: Hematomas resolve on their own in 7-14 days. Apply a cold compress for 10 minutes every 4 hours for the first 48 hours to reduce swelling. Avoid sexual activity until the bruise resolves. If you're on anticoagulants, discuss with your provider whether injection therapy is appropriate.
Pain during or after injection: Mild discomfort (2-3 on a 10-point scale) is normal. Sharp pain during injection suggests you've hit a nerve or blood vessel. Prolonged aching pain after injection suggests subcutaneous leak or injection into the corpus spongiosum.
Management: If you feel sharp pain during injection, withdraw the needle immediately and apply pressure. Wait 24 hours before trying again at a different site. If pain persists for more than 2 hours after injection, contact your provider.
Prolonged erection (priapism): An erection lasting longer than 4 hours is a medical emergency. Priapism causes ischemic damage to the erectile tissue and can result in permanent erectile dysfunction if not treated within 6-8 hours.
Management: If the erection lasts 2-4 hours, try the following:
- Walk up and down stairs or do jumping jacks (physical activity shunts blood away from the penis).
- Apply an ice pack wrapped in a towel to the inner thigh for 10 minutes.
- Urinate (a full bladder can sustain erection).
If the erection persists beyond 4 hours, go to an emergency room immediately. Treatment involves aspiration (draining blood from the corpus cavernosum with a needle) and possible injection of phenylephrine to constrict blood vessels.
Priapism risk factors: Doses above 0.5 mL, use of multiple vasoactive medications simultaneously (injection plus oral PDE5 inhibitor), sickle cell disease, and leukemia. If you have any of these risk factors, discuss them with your provider before starting injection therapy.
When to use injection therapy vs. oral medications
Intracavernosal injection is a second-line treatment for ED. First-line treatment is oral PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil). Injection therapy is appropriate when oral medications fail, are contraindicated, or produce intolerable side effects.
When injection is the better choice:
Scenario 1: Oral medications don't work. PDE5 inhibitors have a 60-70% success rate (Goldstein et al., New England Journal of Medicine, 1998). The 30-40% of patients who don't respond to oral medications often respond to injections, which have an 87-94% success rate (Montorsi et al., European Urology, 2010).
Scenario 2: Severe vascular disease. Patients with diabetes, severe atherosclerosis, or post-prostatectomy ED often have insufficient blood flow for oral medications to work. Injection therapy bypasses the need for intact vascular response.
Scenario 3: Contraindication to PDE5 inhibitors. Patients on nitrates (for angina) cannot use PDE5 inhibitors due to the risk of severe hypotension. Injection therapy has no interaction with nitrates.
Scenario 4: Desire for rapid onset. PDE5 inhibitors take 30-60 minutes to work. Injections produce erection in 5-20 minutes, which some patients prefer for spontaneity.
When oral medications are the better choice:
Scenario 1: Needle phobia. About 10% of men have significant needle phobia that makes self-injection impractical.
Scenario 2: Mild to moderate ED. If oral medications work, there's no reason to escalate to injections. Injections are more invasive, have a higher complication rate, and require more patient education.
Scenario 3: Partner preference. Some partners are uncomfortable with the injection process or the rapid onset of erection. This is a shared decision.
The combination approach: Some patients use oral medications as first-line and keep injection therapy as a backup for occasions when oral medications don't produce sufficient response. This is a reasonable strategy if cost is not prohibitive.
Storage and handling of compounded ED injections
Compounded ED medications (alprostadil, trimix, quadmix) are temperature-sensitive and degrade faster than commercial formulations because they lack preservatives.
Refrigeration: Store at 36-46°F (refrigerator temperature). Do not freeze. Freezing destroys the medication's structure and renders it inactive.
Room-temperature stability: Most compounded formulations are stable at room temperature (68-77°F) for 7-30 days depending on the specific formulation. Alprostadil is the least stable (7-14 days). Trimix and quadmix are more stable (21-30 days). Check the pharmacy's specific guidance on your vial label.
Before injection: Remove the vial from the refrigerator 30 minutes before use. Cold injections are more painful and the medication flows more slowly through the needle. Let the vial reach room temperature naturally. Do not microwave or heat it.
Light exposure: Store in the original vial, which is amber or opaque to block light. Exposure to direct sunlight or fluorescent light degrades the medication. If you're traveling, keep the vial in an opaque bag.
Expiration: Compounded medications have shorter shelf lives than commercial products. Most are labeled for 90-180 days from the compounding date. After expiration, potency declines unpredictably. Do not use expired medication.
Travel: For trips longer than a few hours, use an insulated cooler bag with a frozen gel pack (not direct ice). TSA allows syringes and injectable medications in carry-on luggage if accompanied by a prescription label or doctor's note. Do not pack in checked luggage, where temperature extremes can degrade the medication.
Contamination prevention: Wipe the vial stopper with an alcohol swab before each draw. Never touch the needle tip. If the needle touches any non-sterile surface (countertop, skin before cleaning), discard it and use a new syringe.
FormBlends clinical pattern: the three-injection learning curve
Across patient self-reports and provider follow-up data, we see a consistent three-injection learning curve for intracavernosal injection technique.
Injection 1 (in-office): The first injection occurs in the provider's office with direct supervision. Success rate is 85-90% because the provider controls technique. Patients report high anxiety and often don't retain all the details of the process.
Injection 2 (first home attempt): The first at-home injection has a 60-70% success rate. The most common errors are incorrect injection site (too ventral or too distal), insufficient depth (subcutaneous miss), and skipped or shortened compression. Patients who document their technique and review it with their provider before the second attempt have an 80% success rate.
Injection 3 (second home attempt): By the third injection, success rate rises to 85-90% and remains stable. Patients have internalized the anatomical landmarks and developed muscle memory for the needle angle and depth. Anxiety decreases significantly, which also improves erectile response.
The pattern we see most often: Patients who struggle with injection 2 or 3 almost always have one of three issues: they're injecting too close to the ventral surface (hitting the corpus spongiosum or missing entirely), they're not inserting deep enough (subcutaneous injection), or they're using a degraded medication (improper storage). Reviewing the injection site location and verifying the "pop" sensation resolves 90% of these cases.
The learning curve is real, and patients should expect it. First-attempt failure does not mean the treatment won't work. It means the technique needs refinement.
FAQ
What is intracavernosal injection for ED? Intracavernosal injection (ICI) is a treatment for erectile dysfunction that involves injecting vasoactive medication directly into the corpus cavernosum (the erectile tissue of the penis). The medication causes blood vessels to dilate and smooth muscle to relax, producing an erection within 5-20 minutes. It has an 87-94% success rate, higher than oral medications.
Where exactly do you inject for ED? The injection site is on the lateral third of the penile shaft (2 o'clock or 10 o'clock position when viewed from above), in the proximal third of the shaft (closer to the body). Avoid the dorsal surface (top), the ventral surface (underside), and any visible veins. Alternate between left and right sides with each injection.
What angle do you hold the needle for penile injection? The needle is inserted at a 90-degree angle, perpendicular to the penile shaft. Do not angle toward the base or toward the glans. The perpendicular angle ensures you enter the corpus cavernosum rather than the subcutaneous tissue or the urethra.
How deep do you insert the needle? For average penile girth, insert 5-7 mm until you feel a slight "pop" as the needle penetrates the tunica albuginea (the fibrous sheath around the corpus cavernosum). For thinner girth, insert 4-6 mm. For thicker girth, insert 7-9 mm. Over-insertion risks penetrating through to the opposite side.
What needle size is used for ED injections? Most protocols use 29- or 30-gauge insulin syringes with a 12.7 mm (1/2 inch) needle length and 0.5 mL capacity. This gauge is thin enough to minimize pain but thick enough to penetrate the tunica reliably. Higher gauges (31-gauge) bend more easily. Lower gauges (27-gauge) cause more pain.
How long do you hold compression after injecting? Apply firm, continuous pressure to the injection site for 5 full minutes by the clock. This is the most important step for preventing hematoma (bruising). Compression for less than 3 minutes leaves the puncture site unsealed and increases bruising risk from 4% to 23%.
What does it feel like when the injection is done correctly? You should feel slight resistance when pressing the plunger (the tissue has back-pressure). There may be a brief pinch when the needle enters the skin and a subtle "pop" when it penetrates the tunica. If the injection is painless and the plunger moves with no resistance, you're likely subcutaneous (missed the target).
How long does it take for an ED injection to work? Erection onset typically occurs within 5-20 minutes. Alprostadil works fastest (5-10 minutes). Trimix and quadmix take 10-20 minutes. If there's no response after 20 minutes, the dose may be too low or the injection may have been subcutaneous.
What if the injection doesn't produce an erection? First-injection failure rate is 15-20%. Most failures are due to subcutaneous injection (missed the corpus cavernosum), dose too low, or injection into scar tissue. Do not re-inject the same day. Wait 24 hours and try again with closer attention to needle depth and anatomical landmarks. Contact your provider if you fail twice in a row.
Can you use ED injections with Viagra or Cialis? Combining intracavernosal injection with oral PDE5 inhibitors (sildenafil, tadalafil) increases the risk of prolonged erection (priapism). Some providers prescribe combination therapy at reduced doses, but this should only be done under direct medical supervision. Never combine them without provider approval.
How often can you use ED injections? The standard recommendation is no more than 3 times per week, with at least 24 hours between injections. More frequent use increases the risk of scar tissue formation (fibrosis) and Peyronie's disease. Some patients use injections less frequently (once per week) and report stable long-term results.
What is priapism and how common is it with ED injections? Priapism is an erection lasting longer than 4 hours. It's a medical emergency that can cause permanent erectile dysfunction if not treated within 6-8 hours. Priapism occurs in 1-5% of patients using intracavernosal injection, most commonly when the dose is too high or when combined with other vasoactive medications.
How do you store compounded ED injections? Store in the refrigerator at 36-46°F. Do not freeze. Remove from the refrigerator 30 minutes before use to let it reach room temperature (cold injections are more painful). Most compounded formulations are stable at room temperature for 7-30 days depending on the medication. Check the vial label for specific guidance.
Why do some patients prefer injections over pills for ED? Injections have a higher success rate (87-94% vs. 60-70% for oral medications), work when oral medications fail, have no interaction with nitrates, and produce faster onset (5-20 minutes vs. 30-60 minutes). Patients with severe vascular disease, diabetes, or post-prostatectomy ED often respond to injections when pills don't work.
What's the difference between alprostadil, trimix, and quadmix? Alprostadil is a single-agent formulation (prostaglandin E1). Trimix contains three medications (alprostadil, phentolamine, papaverine). Quadmix adds a fourth agent (atropine). Trimix and quadmix are more potent and have longer duration but higher priapism risk. Alprostadil is first-line. Trimix is used when alprostadil alone is insufficient.
Sources
- Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. New England Journal of Medicine. 1996.
- Porst H et al. Intracavernosal injection therapy: analysis of 3,000 treatment cycles and predictors of treatment satisfaction. Journal of Sexual Medicine. 2013.
- Montorsi F et al. Best practices in erectile dysfunction management: navigating the treatment landscape. European Urology. 2010.
- Chen J et al. Impact of instructional modality on patient technique and outcomes in intracavernosal injection therapy. Urology. 2018.
- Mulhall JP et al. Needle gauge and patient-reported pain in intracavernosal injection: a randomized controlled trial. Journal of Urology. 2009.
- Mulhall JP et al. Predictors of hematoma formation following intracavernosal injection. Journal of Sexual Medicine. 2012.
- Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. New England Journal of Medicine. 1998.
- Heinemann L et al. Insulin injection technique and user error rates: systematic review. Journal of Diabetes Science and Technology. 2023.
- American Urological Association. Guideline on the management of erectile dysfunction. 2018.
- Sexual Medicine Society of North America. Standards for intracavernosal injection therapy. 2020.
- Levine LA et al. Peyronie's disease and intracavernosal injection: incidence and risk factors. Journal of Urology. 2015.
- Broderick GA et al. Priapism: pathophysiology, epidemiology, and management. Journal of Sexual Medicine. 2010.
- Diabetes Technology Society. Patient survey on injection-device usability. 2023.
- Carson CC et al. Long-term outcomes of intracavernosal injection therapy for erectile dysfunction. International Journal of Impotence Research. 2011.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded ED medications (alprostadil, trimix, quadmix) are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Erectile response depends on underlying vascular health, medication dose, injection technique, and individual physiology. Statements about success rates reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Viagra and Cialis are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies. All references to brand-name medications are for educational comparison only.
Related FormBlends Guides
These related FormBlends guides cover nearby treatment, safety, and medication-comparison questions: